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The recent paper by Scholeﬁeld and
colleagues
1 on the 20 year follow-up of the
‘Nottingham’ randomised controlled trial
of guaiac based faecal occult blood test
(gFOBT) colorectal cancer (CRC)
screening, reports an intention to screen
beneﬁt of 13% reduced mortality from
CRC and a participant beneﬁt of 18%
reduction, in spite of offering only biennial
screening and with only 60% ﬁrst round
participation (see page 1036). Their three
‘impact’ statements are an important
basis for progressing screening worldwide
using faecal tests.
The ﬁrst impact statement is that such
screening is worthwhile.
Given that several other controlled trials
of gFOBT screening show mortality
reduction from CRC,
2e5 and that such
screening is considered not only cost
effective but cost saving,
6 this cannot be
disputed. Indeed, it is more than worth-
whiledorganised population based
screening programmes must be imple-
mented. However, a recent publication
reviewing international programmes
shows that fully organised screening is still
in its infancy in many countries.
7 Why
then is CRC screening not universally
accepted and/or fully implemented?
There are many reasons relating to the
population, politics, public health, purse,
providers of healthcare and profession.
Space limitations preclude a full analysis
but this recent paper by Scholeﬁeld et al
1
provides a platform on which to address
some of these.
Their observed impact on CRC
mortality of gFOBT screening was small,
a reduction of just 13%, regardless of its
statistical signiﬁcance.
1 Furthermore,
there was no signiﬁcant impact on inci-
dence despite removal of many advanced
adenomas. Many now consider it possible
to improve on the outcomes demonstrated
in this study and would take the view
that the gFOBT trials provide guidance in
principle as to the value of screening but
not direction on how we should proceed
to implement or evolve screening
programmes at this point in time.
What evidence based options do we
have then to improve the effectiveness of
CRC screening?
One obvious option is to increase the
proportion of people who accept an
invitation to be screened. Both techno-
logical and behavioural strategies can
increase participation. We now know
that the faecal immunochemical test for
haemoglobin (FIT) simpliﬁes the entire
faecal sampling process with consequen-
tial improvement in participation rates.
8
Behavioural strategies that increase
public awareness, such as the use of an
advance notiﬁcation letter, also improve
participation.
91 0
It would have been helpful if Scholeﬁeld
et al had been able to report CRC
mortality beneﬁt relative to the number of
times a participant accepted the invitation
to perform the gFOBT (perhaps because of
lack of power even in a study of this
magnitude). We lack clear guidance on the
degree to which increased frequency of
participation will improve CRC mortality
beneﬁt. Interestingly, their ﬁndings show
that, if screened for just one decade, the
beneﬁt lasts for at least two decades.
Another option to improve effective-
ness is to use a faecal test that can detect
smaller quantities of blood in the faeces
and thus achieve better detection of cancer
and advanced adenomas, ideally without
an unacceptable reduction in speciﬁcity.
This can clearly be achieved using FIT. FIT
is better than gFOBT at detecting cancer
and substantially better at detecting
adenomas.
11 12 Moreover, FIT provides
quantitative faecal haemoglobin measure-
ments that enables the user to choose the
faecal haemoglobin cut-off concentration
that determines who proceeds to diag-
nostic veriﬁcation; this in turn enables
control of the colonoscopy workload.
13 In
the medium sized population controlled
Dutch trial which compared gFOBTwith
FIT,
14 FIT detected twice as many people
with advanced neoplasia (ie, cancer or
‘advanced’ adenomas) than gFOBT. While
the colonoscopic effort was twice that
used for gFOBT, the marked increase in
lesion detection seems worth the effort.
Scholeﬁeld et al report that, in the
invited group, an extra 615 ‘advanced’
adenomas were identiﬁed as being removed
following a positive gFOBT.
1 Since their
study had 90% power to detect a 10%
difference in incidence between groups, and
since each group had about 2200 cancers,
then a strategy that reduced incidence of
cancer by about 220 might have proved
signiﬁcant. Putting it another way,
removing 615 advanced adenomas failed to
prevent 220 cancers in the time frame of
observation. That this effect was not
observed led Scholeﬁeld et al to speculate
that adenoma dwell time might be longer
than 10e15 years. Alternatively, or in
addition, it might be that less than one-
third of advanced adenomas are destined to
progress to cancer. Whatever the case and
despite these crude calculations, if an
impact on incidence within two decades is
to be attained, detection and removal of
more adenomas than was achieved in this
trial seems mandatory. This is supported
by the comments by Scholeﬁeld et al on the
Minnesota trial where a reduction in CRC
incidence was observed by using a more
sensitive and less speciﬁct e s t drehydrated
gFOBTdthus returning a much higher test
positivity rate with a consequently greater
rate of adenoma removal.
2
CRC screening using faecal tests has the
capacity to prevent cancer by detection
and removal of adenomas if the test used
is sufﬁciently sensitive.
15 Whether the
extra effort needed to improve adenoma
detection and removal is feasible, afford-
able or considered cost effective remains
an issue for debate but the results reported
by Scholeﬁeld et al indicate that a low
sensitivity gFOBT will not reduce inci-
dence. How many adenomas really do
need to be removed to prevent one cancer
is the unanswered question.
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CommentaryTheir second impact statement is that
the ‘National Bowel Cancer Screening
Programme’ would be expected to deliver
a CRC mortality reduction (it should be
noted that four countries are screening in
the UK and their approaches differ). While
such an impact is very likely, it seems
accepting of a small beneﬁt when a greater
beneﬁt is achievable. With FIT, we now
have faecal screening tests that are more
acceptable to participants and possess
markedly better analytical and clinical
performance characteristics. When used at
conventional cut-off concentrations, FIT
usually requires more follow-up colonos-
copies but the effort is not dispropor-
tionate to the improvements in lesion
detection.
14 Furthermore, the use of
a quantitative FITenables objective choice
of the desirable clinical performance char-
acteristics, something gFOBT cannot
deliver. The challenge for a CRC screening
programme is to develop a high quality
colonoscopy resource so that the many
operational, analytical and clinical advan-
tages of FITcan be effectively exploited.
In short, current evidence makes it clear
that using gFOBT for screening is a choice
for a less effective test. This is why the
European Guidelines for CRC Screening
now recommend the use of FIT.
16
Scholeﬁeld et al implied support for this
conclusion in their third impact statement
which states that the door is open to new
screening methodologies, speciﬁcally
‘immunological (sic) FOBt’. In 1993e1996,
the initial publications of the randomised
controlled trials of gFOBT screening
proved population beneﬁt
231 7 ; two
decades later we have a proven, improved
screening testdFIT! gFOBT has success-
fully underpinned many efforts in
screening but FIT provides enhanced
analytical, logistical and clinical attributes
that allow successful management of
workloads and optimisation of clinical
performance. Whether gFOBT passes into
history in CRC screening is now in the
hands of those who organise large scale
programmes.
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